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Abstract
Background: Molecular markers for localized colon tumours and for prognosis following therapy
are needed. Proteomics research is currently producing numerous biomarker studies with clinical
potential. We investigate the protein composition of plasma and of tumour extracts with the aim
of identifying biomarkers for colon cancer.
Methods: By Surface Enhanced Laser Desorption/Ionisation – Time Of Flight / Mass spectrometry
(SELDI-TOF/MS) we compare the protein profiles of colon cancer serum with serum from healthy
individuals and the protein profiles of colon tumours with normal colon tissue. By size exclusion
chromatography, we investigate the binding of HNP 1-3 to high mass plasma proteins. By microflow
we investigate the effect of HNP 1-3 on mammalian cells.
Results: Human Neutrophil Peptides -1, -2 and -3 (HNP 1-3), also known as alfa-defensin-1, -2 and
-3, are present in elevated concentrations in serum from colon cancer patients and in protein
extracts from colon tumours. A fraction of HNP 1-3 in serum is bound to unidentified high mass
plasma proteins. HNP 1-3 purified from colon tumours are lethal to mammalian cells.
Conclusions: HNP 1-3 may serve as blood markers for colon cancer in combination with other
diagnostic tools. We propose that HNP 1-3 are carried into the bloodstream by attaching to high
mass plasma proteins in the tumour microenvironment. We discuss the effect of HNP 1-3 on
tumour progression.
Background
The diagnostic stage of colon cancer determines survival.
Patients diagnosed with localized tumours have a 75%
probability of 5 year survival, whereas patients diagnosed
with distant metastases only have a 5–10 % probability of
5 year survival (reviewed in [1]). Recently a number of
studies have been published in which Surface Enhanced
Laser Desorption/Ionisation-Time Of Flight/Mass Spec-
trometry (SELDI-TOF/MS) has been applied to biological
samples from patients with various forms of cancer [2-4]
leading to the identification of protein markers with clin-
ical potential. Here we present a SELDI-TOF/MS study of
colon cancer serum and tumours. We show that the
expression of Human Neutrophil Peptides -1, -2 and -3
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(HNP 1 -3), also known as alfa-defensin-1, -2 and -3, is
upregulated in the tumour microenvironment, as com-
pared to normal colon tissue. This finding is reflected in
serum. We find that HNP 1-3 is present in elevated con-
centrations in serum from patients diagnosed with
tumours in the colon, as compared to serum from a
healthy control group matched by age and gender. By size-
exclusion analysis we add to the existing evidence that
HNP 1-3 bind to high mass plasma proteins, explaining
the presence of HNP 1-3 in serum. By microflow analysis,
we show that HNP 1-3 purified from colon tumours are
lethal to mammalian cells. The HNP 1-3 peptides are part
of the defensin family of peptides (reviewed in [5-7]),
which are a fundamental component of the immune sys-
tem and have the capacity to kill / inactivate a broad range
of pathogens. Defensins are also known to function as
regulators of both the innate and the adaptive immune
system. We discuss the possible effects of HNP 1-3 in the
tumour microenvironment.
Methods
Biological samples
All biological samples were obtained by trained staff at
Glostrup Hospital, Denmark. Written consent was
obtained from all donators. Permission was obtained
from the Danish Scientific Ethical Committee and the
Danish Data Protection Agency.
Tissue screening
Normal colon tissue samples and colon tumour samples
were obtained from the removed fragment of the patient's
colon after surgical treatment for colon cancer. Tissue
samples were stored at -80°C until use. The protein con-
tent was extracted from the tissue: 100 mg tissue sample
was thawed on ice and homogenised on a Wheaton Over-
head Stirrer for 2 minutes at speed step 2, in 500 ul Lysis
buffer (100 mM TRIS-HCl, pH 8.0, 9.5 M UREA, 2%
CHAPS). The samples were centrifuged at 14,000 rpm for
10 minutes and the pellet was discarded (repeated twice).
The tissue protein extracts were stored at -80°C until use.
Pilot studies were performed on different chips (data not
shown) and the NP20 (Normal Phase) (Ciphergen) chip
was chosen for the tissue screening. NP20 chips were
placed in Bioprocessor (Ciphergen) and pre-treated with
50 ul tissue binding buffer (50 mM TRIS-HCl, pH 8.0) for
5 minutes on shaker (250 rpm) (repeated twice). 5 ul tis-
sue protein extract was diluted in 50 ul tissue binding
buffer and incubated in Bioprocessor on NP20 chips for
40 minutes at room temperature on shaker (250 rpm).
Spots were washed twice in 250 ul tissue washing buffer
(50 mM TRIS-HCl, pH 8.0) for 5 minutes. The chips were
air dried for 10 minutes, followed by treatment with two
times 0.6 ul 100% sinapinic (SPA) matrix solution. SPA
was obtained from Ciphergen in 5 mg aliquots and dis-
solved (150 ul MQ water, 150 ul acetonitrile, 1.5 ul Tri-
Fluoro-acetic-Acid (TFA)) immediately before the
screenings.
Serum screening
Colon cancer serum samples were obtained from patients
before surgical treatment. Normal serum was obtained
from a group of healthy individuals matched by age and
gender to the cancer patients. All serum samples were
stored at -80°C until use. Serum pilot studies were per-
formed on different chips to monitor the presence of HNP
1-3 in serum (data not shown). The immobilised metal
affinity capture (IMAC30) chip was chosen for the actual
screening and was pre-treated with nickel before analysis:
5 ul 100 mM NiSO4 were added to each spot and left on
shaker (250 rpm) for 5 minutes (repeated twice). The
chips were placed in Bioprocessor and incubated with 100
ul MQ for 5 minutes on shaker (250 rpm). Each spot was
treated with 50 ul serum binding buffer (100 mM TRIS-
HCl, pH 7.5, 500 mM NaCl, 0,1% Triton X-100) and left
on shaker for 5 minutes (250 rpm). Serum samples were
thawed on ice and 1 ul serum was diluted in 50 ul serum
binding buffer and applied to spots and left on shaker
(250 rpm) at room temperature for 40 minutes. The sam-
ple solution was removed and the spots were washed
twice in 200 ul serum washing buffer (100 mM PBS, pH
7.4, 700 mM NaCl), followed by one wash in 200 ul MQ
water. The chips were removed from the Bioprocessor and
left to air dry for 20 minutes followed by treatment with
two times 0.6 ul SPA.
Only freshly made matrix solutions were used and the
instrument was calibrated daily. Cancer and normal sam-
ples were run side by side. The chips were analysed on a
PBS II instrument (Ciphergen). All spectra in each screen-
ing were normalised based on total ion current.
Purification and identification of HNP 1-3
100 ul protein extract from colon tumour tissue in tissue
lysis buffer was loaded unto a RP-HPLC column (uRPC
C2/C18 ST 4.6/100, Pharmacia Biotech, Flow rate: 0.5 ml/
min, Fraction size: 0.5 ml) in buffer A (0.065% TFA in
MQ-water) and proteins were eluted in a gradient of 0–
100% buffer B (0.05% TFA in acetonitrile (ACN)). Elution
of peptides was monitored by absorbance at 280 nm. All
protein-containing fractions were analysed by Matrix
Assisted Laser Desorption/Ionisation-Time of flight
(MALDI-TOF) on the PBS II instrument: 1.5 ul fraction
was incubated with 0.6 ul SPA on a Gold array (Cipher-
gen) and left to crystallise, followed by an additional treat-
ment with 0.6 ul SPA and analysed in the PBSII
instrument. The HNP 1-3 containing fraction (32% buffer
B) was further purified on a peptide gelfiltration column
(Superdex Peptide HR 10/30, Pharmacia Biotech, Flow
rate 0.9 ml/min, Fraction size: 0.5 ml, Buffer: 50% ACN,
0.1 % TFA). Elution of peptides was monitored byBMC Cancer 2005, 5:8 http://www.biomedcentral.com/1471-2407/5/8
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absorbance at 280 nm and protein-containing fractions
were again analysed by MALDI-TOF. Purified HNP 1-3
were identified by on-chip trypsin digestion: 10 ul of HNP
1-3 fraction was applied to an NP20 chip and left on
shaker (250 rpm) at room temperature for 40 minutes.
The solution was removed and the spot was washed twice
with 10 ul water. In order to denature peptides prior to
digestion, the chip was left on heating block (80°C) for 5
minutes. The chip was cooled on ice for 2 minutes. 10 ul
trypsin digestion solution (0.01 ug/ul trypsin in 50 mM
NH4HCO3, pH 8,0) was added, and the chip was left for
10 hours at 40°C in humidity chamber after which the
chip was left to air dry for 20 minutes. 1 ul CHCA matrix
(prepared as the SPA matrix solution) was added and the
peptide map was analysed on the PBS II instrument. Pep-
tide maps of trypsin autodiggest were used as controls.
Identification was done with the PepIdent software on the
Expasy server. For the reduction experiment, HNP 1-3
were first denaturation by heating (10 minutes at 80°C)
followed by treatment with DTT (200 mM, 30 minutes at
room temperature) and the peptides were incubated on
an NP20 chip and analysed on the PBS II instrument.
Size exclusion chromatography of HNP 1-3
50 ul colon cancer serum was loaded unto a peptide gel-
filtration column (Superdex Peptide HR 10/30, Pharma-
cia Biotech, optimal separation range: 1 to 7 kDa, flow
rate: 0.5 ml/min, fraction size: 0.5 ml, buffer: 10 mM
Ammonium carbonate, pH: 8.0). Elution of peptides was
followed by absorbance at 280 nm. All protein containing
fractions were analysed by MALDI-TOF on PBS II (Cipher-
gen) as described above. Maximum signal intensity of 40
individual peaks was plotted as a function of elution vol-
ume and an approximate elution curve was calculated.
Study of HNP 1-3 by microflow
For micro flow experiments, canine kidney cells (MDCK
cells) were plated onto poly-d-lysine coated cover slips at
a concentration 3000 cells/well, grown in Dilbeccoo's
Modified Eagle Medium (DMEM) with 10% Fetal Bovine
Serum (FBS) for five days with the result of confluent
islands. Microflow was performed in an Eppendorf micro-
manipulator 5171 and transjector 5246 system mounted
on a Leica DMIRBE inverted research microscope. Micro
capillaries (borosilicate with filament, Sutter Instruments
Company, Novato, California, USA) were pulled to an
outer diameter of 0.85 nm on a Sutter P-97 Micropipette
Puller. The dye-loaded cells were visualized by excitation
at 470 nm and recorded at 509-nm emission using
Haupage version 3.3.18038 software and Kappa CF 15/4
MC-S camera (Leica). The MDCK cells were recorded (in
CO2 independent media) on the inverted DMIRBE
inverted research microscope. The capillary was placed 20
nmover the confluent cells with a constant flow (1300
hPa). The MDCK cells were exposed to peptide and cal-
cein (20 mM) fractions for 60 minutes.
Results
HNP 1-3 expression in tissue and serum
We performed pilot studies of colon tumour and normal
colon tissue on a variety of chips with different chemical
properties and with different binding and washing condi-
tions. Based on these preliminary studies, we found that
the expression of three peptides with mass/charge ratio
(m/z) values of 3372, 3443 and 3486 (subsequently iden-
tified as HNP 2, 1 and 3, respectively), were upregulated
in the tumour samples. The three peptides were visible on
different chips and under different binding conditions
(data not shown). The strongest signal of HNP 1-3 in tis-
sue extract was obtained on the NP20 (Normal Phase)
chip, whereas the strongest signal of HNP 1-3 in serum
was observed on the IMAC30 (Ni) (immobilised metal
affinity capture chip, activated with nickel), and these
conditions were chosen for the actual screenings. We
emphasize that in general the protein profiles of serum
and tissue were very different when using the same pro-
tein chip for serum and tissue extract. However, individ-
ual peaks were present on several types of chips, and
observed in both serum and in tissue extract, for example
the characteristic triplet with m/z 3372, 3443 and 3486.
Protein extract from 40 colon tumour and 40 normal
colon tissue samples were analysed on NP20 chips and
125 colon cancer serum samples and 100 normal serum
samples were analysed on IMAC30 (Ni) chips. All spectres
in each screening were pooled and normalised based on
overall ion current. Each spectrum produced approxi-
mately 40 to 90 protein peaks in the range from 2 to 80
kDa (FIG. 1A–C). Statistical analysis of the intensity val-
ues of HNP 1-3 in the tissue screening (FIG. 2A.) showed
that HNP 1-3 were significantly upregulated in tumours
(p < 0.0005) and statistical analysis of HNP 1-3 expres-
sion in the serum screening (FIG. 2B.) showed that HNP
1-3 were significantly upregulated in cancer serum (p <
2.2e-16).
Compared to other peptides in the same range, HNP 1-3
showed average signal intensity in most normal colon tis-
sue extract, whereas the HNP 1-3 signal was extremely
high in most tumour samples (in some tumour spectres
the HNP 1-3 peaks were the strongest of all peaks). In the
normal serum samples the HNP 1-3 signals were weak
and only slightly stronger in the cancer serum.
Identification of HNP 1-3
The markers were purified by RP-HPLC, peptide gelfiltra-
tion and on-chip purification, after which they were iden-
tified by peptide mapping as HNP-2 (3372 Da), HNP-1
(3442 Da) and HNP-3 (3486 Da) (Table 1A). The masses
correspond to the peptides in their oxidised states withBMC Cancer 2005, 5:8 http://www.biomedcentral.com/1471-2407/5/8
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three disulfide bridges. After reduction with DTT, HNP-1
and HNP-2 increased 6 Daltons in mass, due to reduction
of the six cysteines (Table 1B). We were not able to reduce
HNP-3.
Size exclusion chromatography of HNP 1-3
50 ul colon tumour extract in Lysis buffer was applied to
a peptide gelfiltration column. Elution of peptides was
followed by absorbance at 280 nm. All fractions were ana-
lysed by MALDI-TOF on the PBS II instrument (Cipher-
gen). Maximum signal intensity of 40 individual peaks
was plotted as a function of the elution volume and an
approximate elution curve was calculated (FIG. 3). HNP
1-3 peptides were primarily eluted in early fraction
together with high mass proteins above 20 kDa and also,
but to a lesser degree, in fractions together with other pep-
tides of similar mass interval (2 to 4 kDa) (FIG. 3).
Cytoxic assay
The cytotoxicity of HNP 1-3 purified from colon tumours
was tested by exposing MDCK cells to different fractions
purified from colon tumours. Calcein were added to the
fractions and the solutions were left to flow over the cells
for one hour. By fluorescence microscopy calcein was
observed to accumulate in cells exposed to HNP 1-3/cal-
cein fractions, whereas cells treated with fractions contain-
ing other (unidentified) tissue peptides did not uptake
calcein (FIG. 4C&D). Further, by microscopy we observed
that cells exposed to HNP 1-3 appeared more diffuse and
had enlarged nuclei, indicating apoptosis (FIG. 4A&B).
Discussion
Elevated concentrations of HNP 1-3 in colon cancer serum
Abnormal concentration of HNP 1-3 in blood has previ-
ously been demonstrated in connection with benign con-
ditions. Elevated concentrations of HNP 1-3 following
infection (bacterial- / non-bacterial- infection and pulmo-
nary tuberculosis) has been found in plasma, blood and
other body fluids [8], and plasma HNP 1-3 concentrations
have been shown to be elevated in patients with septi-
cemia or bacterial meningitis [9]. HNP 1-3 have been
found in urine from patients with transitional cell carci-
noma of the bladder [10] and HNP-1 has been found in
salvia of patients with oral carcinomas [11]. Finally, HNP
1-3 are found in excess amounts in tears after ocular
Protein profiles of serum and tissue Figure 1
Protein profiles of serum and tissue. Representative SELDI-TOF/MS spectra of normal colon tissue (FIG. 1A) on the 
NP20 chip and normal serum (FIG. 1B) on the IMAC30 (Ni) chip. The two spectra differ significantly and each produce a total 
of 40 to 60 peaks. The majority of the peaks are present in the specified range from 2 to 10 kDa. FIG. 1C Comparison of a typ-
ical colon tumor spectrum (above) and a normal colon spectrum (below) in the range from 3 to 4 kDa. The arrows point to 
the three differentially expressed peptides, subsequently identified as HNP 1-3. The three peptides are expressed in normal 
colon tissue and the expression is upregulated in the tumor samples. The three peptides are present in normal serum, but are 
present in higher concentrations in colon cancer serum. The average peak intensity for the three peptides were significantly 
lower in serum than in tissue.BMC Cancer 2005, 5:8 http://www.biomedcentral.com/1471-2407/5/8
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Expression of HNP 1-3 in tumors and serum Figure 2
Expression of HNP 1-3 in tumors and serum. FIG.2A HNP 1-3 profiles of normal and colon tumor tissue. 40 colon 
tumor and 40 normal colon tissue samples were analysed on NP20 chips. Differences in mean intensities of HNP 1-3 in normal 
and colon tumor tissue were statistical significant at 5% level (p < 0.0005). FIG. 2B HNP profiles of normal and colon cancer 
serum. Serum samples (125 colon cancer and 100 normal) were analyzed on IMAC30 chips. The mean intensities were signifi-
cantly different at 5% level (p < 2.2e-16). The reproducibility was significant for all three peptides in both tissue and serum. The 
standard deviation of HNP 1, 2 and 3 was 70%, 136% and 57% in normal tissue and 11%, 15% and 8% in tumor tissue. The 
standard deviation of HNP 1, 2 and 3 was 96%, 154% and 81% in normal serum and 234%, 365% and 282% in cancer serum. 
The boxplot show the 25th quantile, median, 75th quantile, and whiskers extent to min. and max. values.BMC Cancer 2005, 5:8 http://www.biomedcentral.com/1471-2407/5/8
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surface surgery [12]. Our study is the first that demon-
strate elevated concentrations of HNP 1-3 in blood fol-
lowing tumour growth.
Elevated concentrations of HNP 1-3 in colon tumours
HNP expression has previously been linked to different
types of tumours and cell lines. HNP-1 has been detected
in lung tumours [13] and in the submandibular glands of
patients with oral carcinomas [14]. By RT-PCR, mass spec-
trometry and flow cytometric analysis, HNP 1-3 have
been shown to be expressed by cell lines deriving from
renal cell carcinomas [15] and the expression of a specific
HNP precursor peptide has been shown to be upregulated
in human leukemic cells [16]. Our results suggest that
HNP 1-3 are extremely abundant in colon tumours. This
is in agreement with a study of HNP-1 in lung tumours,
where the maximum observed level was 26 nanomoles
per gram wet tissue [13]. In order for these excessive
amounts of peptide to be detectable in serum, the pep-
tides must be present extracellular in the tumour environ-
ment, such as observed in studies of HNP 1-3 expression
in kidney [14] and brain [17]. Usually tumour expressed
peptides are not easily detected in serum or plasma by
SELDI-TOF mass spectrometry techniques; the highly con-
centrated plasma proteins out compete the signal of low
abundance peptides. We suggest that HNP 1-3 are detect-
able in serum only because they are expressed in excep-
tionally high amounts in the tumour microenvironment.
Previous studies indicate that HNP 1-3 expression in
tumours primarily originate from tumour invading eosi-
nophils [13] and neutrophils [14,18]. However, it has
been shown that the excess amounts of HNP 1-3 observed
in urine from bladder cancer patients were often produced
by the actual bladder cancer cells [10], and that highly
invasive bladder cancer cells produced more HNP 1-3
than less invasive ones (Holterman DA, in press, personal
communication). Since our tissue screening is based on
comparison of tissue samples, we cannot say whether the
peptides are produced by the colon cancer cells or by
tumour infiltrating neutrophils. In the case of active
inflammatory bowel disease, it is not clear whether epi-
thelial expression of HNP1-3 is induced by the inflamma-
tory state or the whether the peptides are released by
adjacent neutrophils and taken up by the epithelial cells
[6]. Here it is believed that the peptides provide protec-
tion against microbial invasion when the mucosal barrier
is damaged (such as is the case in inflammatory bowel dis-
eases). HNP 1-3 are known to stimulate bronchial epithe-
lial cells to upregulate interleukin-8 production [19], a
potent neutrophil chemotactic factor. Thus, the upregu-
lated expression of HNP 1-3 in tumours may primarily
originate from invading immune cells, but could be initi-
ated by HNP 1-3 producing cancer cells.
Size exclusion chromatography of HNP 1-3
We explain the elevated concentrations of HNP 1-3 in
colon cancer serum by unspecific binding between HNP
1-3 and high mass plasma proteins. We suggest that the
peptides attach to plasma proteins in the tumour area and
are carried into the bloodstream. The HNP 1-3 we observe
in high mass fractions from size exclusion, could also be
explained by multimerisation: In one study it was demon-
strated that defensins form voltage dependent channels in
Table 1: Identification of HNP 1-3. Table 1A HNP 1-3 peptides were identified by peptide mapping (on-chip trypsin digest). Three 
sequence specific fragments were produced (615.8, 930.6, 1061.4 Da.). The peptides were identified as HNP 1-3 using the PepIdent 
server on the ExPASy homepage. Table 1B The measured masses of the HNP 1-3 peptides were approximately 6 Daltons lower than 
the expected theoretical masses. This deviation was caused by the in vivo formation of three disulfide bridges. By heat denaturation 
and treatment with DTT we were able to protonate the six cysteines in HNP 1 and 2. (HNP-3 was consistently degraded during the 
reduction procedure).
A
Measured masses from 
peptide mapping (Dalton)
Matching theoretical masses 
(Dalton)
Deviation (Dalton) Peptide sequence
615.8 615.7 +0.1 ACYCR
930.6 930.1 +0.5 IPACIAGE
1061.4 1061.2 +0.2 YGTCIYQ
B
Measured masses of HNP 1-3 
peptides (Dalton)
Theoretical masses of HNP 1-
3 peptides (Dalton)
Measured masses of reduced 
HNP 1-3 peptides (Dalton)
3371.2 3377.0 (HNP-2) 3376.2
3442.3 3448.1 (HNP-1) 3448.6
3486.3 3292.1 (HNP-3) -BMC Cancer 2005, 5:8 http://www.biomedcentral.com/1471-2407/5/8
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lipid bilayer membranes and further conductance investi-
gations suggested that the channels were formed by mul-
timers containing 2–4 molecules [20] and a crystal
structure study [21] of HNP-3 revealed an amphiphilic
dimmer. We interpret the size exclusion results as evi-
dence for interaction between HNP 1-3 and unidentified
high mass proteins through unspecific interactions; the
peptides are eluted in very early fractions which would
probably require the presence of multimers of more than
five peptides and our study does not reveal the presence of
multimers containing four, three or two peptides. Further,
our interpretation is in agreement with a number of previ-
ous studies that show that HNPs are bound to plasma pro-
tein in vitro and that high concentrations of HNPs causes
precipitation of plasma proteins; specifically 2-macro-
glubulin and C1 complement [22,23] has been shown to
bind defensin. Another study [24] showed that HNP-1
bind to various plasma proteins, notably serum albumin,
and it was found that serum, or serum albumin, was able
to inhibit the anti-viral activity of HNP-1. This ability to
bind to plasma proteins could also explain why HNP 1-3
lysis of mammalian cells is hindered in the presence of
serum [25]. Together these observations add to the grow-
ing realisation that common plasma proteins may carry
disease specific peptides and therefore should not be
ignored in biomarker research.
Common to beta-defensin 2 (another member of the
defensin family) and HNP 1-3 is an uneven distribution
of surface charges. Beta-defensin 2 has been shown to
bind to a chemokine receptor [26]. It has been suggested
that the positively charged cluster found in defensin pep-
tides and chemokines, may play a common role in bind-
ing to receptors, but is not important for determining
receptor specificity [27]. This surface charge may also
explain the binding of HNP 1-3 to plasma proteins. The
Size exclusion study of HNP 1-3 Figure 3
Size exclusion study of HNP 1-3. Protein extract from tumor tissue was separated on a peptide gelfiltration column. The 
elution volumes of forty (unidentified) peptides was plotted against their respective mass values and an approximate elution 
curve was calculated. The arrows point to HNP 1-3, which were eluted in two fractions: primarily in the void volume (8 ml) 
together with high mass proteins (above 20 kDa) and after 14 ml together with peptides of similar mass range (2–4 kDa). We 
interpret this as evidence for binding between HNP 1-3 and high mass proteins.BMC Cancer 2005, 5:8 http://www.biomedcentral.com/1471-2407/5/8
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observation that defensins are localised to lymphocyte
nuclei [28], could similarly be explained by unspecific
binding to shuttle proteins.
The function of HNP 1-3
The exact concentration of HNPs in the tumour microen-
vironment may decide the in vivo function of HNP 1-3.
One study showed that HNP 1-3 mediates lysis of
tumours in a concentration dependent manner [25]. This
is in agreement with another study that show that only rel-
atively high concentrations of HNP-1 (10-4 M) are cyto-
toxic for human monocytes, whereas lower concentration
of HNP-1 (10-8 to 10-9 M) increases TNF-alpha production
by monocytes [29]. In a study of renal cell carcinoma lines
[14] it was shown that HNP 1-3 were cytotoxic to all tested
cell lines when present in high concentrations (above 25
ug/ml), but at lower concentration HNP 1-3 stimulated
growth of a subset of tumour cell lines. We add to these
results by demonstrating that in vivo HNP 1-3 purified
from colon tumours are capable of lysing MDCK cells.
Functional study of HNP 1-3 Figure 4
Functional study of HNP 1-3. Normal microscopy (A&B) and flourescence microscopy (C&D) of MDCK cells. MDCK cells 
were exposed to calcein with (A&C) and without HNP 1-3 (B&D). By fluorescence microscopy (C&D) the cells were observed 
to uptake calcein only when treated with fractions containing HNP 1-3/calcein (C). Fractions containing unidentified peptides 
purified from colon tumors were used as negative controls together with calcein and did not stimulate the cells to uptake cal-
cein (D). Cell islands treated with HNP 1-3 appeared diffuse and showed enlarged nuclei, indicating apoptosis (A).BMC Cancer 2005, 5:8 http://www.biomedcentral.com/1471-2407/5/8
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Our study was based on a 60 minutes microflow study.
This screening set-up did not allow us to investigate the
minimum concentration of HNP 1-3 necessary for lysis.
Conclusions
The high concentration of HNP 1-3 observed in tumours
and the observation that HNP 1-3 are capable of lysing
mammalian cells may lead to the conclusion that the pep-
tides serve to the benefit of the host by killing tumour
cells. However, in one study HNP 1-3 were found to bind
to HLA-Class II molecules and were capable of reducing
the proliferation of a HLA-DR-restricted T-cell line after
stimulation [30] and could in this way help the cancer
cells avoid local immune recognition. Defensins also reg-
ulate the systemic immune response. Through interaction
with the chemokine receptor CCR6, beta-defensins
recruits dendritic and T cells[26] (discussed in [31]) and
HNP 1-3 are capable of recruiting leukocytes to sites of
infection in mice [32]. Upregulated immune responses
are known to stimulate tumour proliferation; immune
cells are actively recruited by tumours to exploit their pro-
angiogenic and pro-metastatic effects (reviewed in
[33,34]). Whether the high concentrations of HNP 1-3 in
the tumour limits the tumour growth or on the contrary
stimulate tumour proliferation is not clarified; we empha-
sise that HNP 1-3 are expressed in inflammatory bowel
disease and could be involved in the early stages of car-
cinogenesis. We suggest that the prominent surface charge
on defensins, their unspecific binding to other proteins
(such as high mass plasma proteins) and the observed
excess amounts of peptides found in tumours, could pro-
vide the peptides with broad antagonising effects on
numerous receptors in the tumour microenvironment. In
this way HNP 1-3 peptides may serve to the benefit of the
tumour.
Our results add to the evidence that HNP 1-3 bind to high
mass plasma proteins. We suggest that the peptides are
released in the inflammatory site and passively diffuse
into the blood stream. HNP 1-3 have been observed in
primary tumours of different tissues and the peptides are
known to play a fundamental role in the innate immune
system. We suggest that the peptides may serve as markers
for colon cancer in combination with established diag-
nostic tools and as prognostic markers following therapy.
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